Literature summary for 3.4.14.5 extracted from

Biftu, T.; Feng, D.; Qian, X.; Liang, G.B.; Kieczykowski, G.; Eiermann, G.; He, H.; Leiting, B.; Lyons, K.; Petrov, A.; Sinha-Roy, R.; Zhang, B.; Scapin, G.; Patel, S.; Gao, Y.D.; Singh, S.; Wu, J.; Zhang, X.; Thornberry, N.A.; Weber, A.E.
(3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes (2007), Bioorg. Med. Chem. Lett., 17, 49-52.

Inhibitors

Inhibitors	Comment	Organism
(3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one	competitive, reversible inhibitor. Pharmacokinetic parameters	Canis lupus familiaris
(3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one	competitive, reversible inhibitor	Mus musculus
(3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one	competitive, reversible inhibitor. Pharmacokinetic parameters	Rattus norvegicus
(3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-methyl-1,4-diazepan-2-one	pharmacokinetic parameters	Canis lupus familiaris
(3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-methyl-1,4-diazepan-2-one	pharmacokinetic parameters	Mus musculus
(3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-methyl-1,4-diazepan-2-one	pharmacokinetic parameters	Rattus norvegicus

Organism	UniProt	Comment	Textmining
Canis lupus familiaris	-	-	-
Mus musculus	-	-	-
Rattus norvegicus	-	-	-

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)